Could OKYO Pharma’s urcosimod finally crack a painful eye disease with no approved therapy?
OKYO Pharma’s urcosimod moves toward Phase 3 as the biotech targets neuropathic corneal pain, a severe ocular condition without approved therapy.
Pharma & Biotech
Pharma & Biotech
How urcosimod’s FDA compassionate use authorization reshapes development risk in ocular neuropathic pain
FDA allows compassionate use of urcosimod for neuropathic corneal pain. Read how this decision reshapes regulatory, clinical, and development risk.